Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129719013> ?p ?o ?g. }
- W2129719013 endingPage "775S" @default.
- W2129719013 startingPage "708S" @default.
- W2129719013 abstract "This chapter about fibrinolytic, antiplatelet, and antithrombin treatment for acute ST-segment elevation (STE) myocardial infarction (MI) is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patient values may lead to different choices (for a full understanding of the grading see the chapter by Guyatt et al, CHEST 2008; 133[suppl]:123S–131S). Among the key recommendations in this chapter are the following: for patients with ischemic symptoms characteristic of acute MI of ≤ 12 h in duration and persistent STE, we recommend that all undergo rapid evaluation for reperfusion (primary percutaneous coronary intervention [PCI] or fibrinolytic) therapy and have a reperfusion strategy implemented promptly after contact with the health-care system (Grade 1A). For patients with ischemic symptoms characteristic of acute MI of ≤ 12 h in duration and persistent STE, we recommend administration of streptokinase, anistreplase, alteplase, reteplase, or tenecteplase over no fibrinolytic therapy (all Grade 1A). For patients with symptom duration ≤ 6 h, we recommend the administration of alteplase or tenecteplase over streptokinase (both Grade 1A). We recommend aspirin over no aspirin therapy followed by indefinite therapy (Grade 1A); we also recommend clopidogrel in addition to aspirin for up to 28 days (Grade 1A). In addition to aspirin and other antiplatelet therapies, we recommend the use of antithrombin therapy (eg, unfractionated heparin (UFH), enoxaparin, or fondaparinux) over no antithrombin therapy (Grade 1A), including for those patients receiving fibrinolysis (and regardless of which lytic agent is administered), primary PCI, or patients not receiving reperfusion therapy. This chapter about fibrinolytic, antiplatelet, and antithrombin treatment for acute ST-segment elevation (STE) myocardial infarction (MI) is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patient values may lead to different choices (for a full understanding of the grading see the chapter by Guyatt et al, CHEST 2008; 133[suppl]:123S–131S). Among the key recommendations in this chapter are the following: for patients with ischemic symptoms characteristic of acute MI of ≤ 12 h in duration and persistent STE, we recommend that all undergo rapid evaluation for reperfusion (primary percutaneous coronary intervention [PCI] or fibrinolytic) therapy and have a reperfusion strategy implemented promptly after contact with the health-care system (Grade 1A). For patients with ischemic symptoms characteristic of acute MI of ≤ 12 h in duration and persistent STE, we recommend administration of streptokinase, anistreplase, alteplase, reteplase, or tenecteplase over no fibrinolytic therapy (all Grade 1A). For patients with symptom duration ≤ 6 h, we recommend the administration of alteplase or tenecteplase over streptokinase (both Grade 1A). We recommend aspirin over no aspirin therapy followed by indefinite therapy (Grade 1A); we also recommend clopidogrel in addition to aspirin for up to 28 days (Grade 1A). In addition to aspirin and other antiplatelet therapies, we recommend the use of antithrombin therapy (eg, unfractionated heparin (UFH), enoxaparin, or fondaparinux) over no antithrombin therapy (Grade 1A), including for those patients receiving fibrinolysis (and regardless of which lytic agent is administered), primary PCI, or patients not receiving reperfusion therapy. ErrataCHESTVol. 134Issue 4PreviewIn the June 2008 supplement, in the article by Goodman et al, “Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (Chest 2008; 133[suppl]:708S–775S), on page 710S, in column one, Recommendation 2.5.2 (and on page 739S column one), the text should read “For patients with acute ST-segment elevation myocardial infarction receiving fibronolytic therapy who have preserved renal function (< 2.5 mg/dL [220 μmol/L] in males and < 2.0 mg/dL [175 μmol/L] in females), we recommend the use of enoxaparin over UFH, continued up to 8 days (Grade 2A).” The online version has been corrected and that version should be used. Full-Text PDF" @default.
- W2129719013 created "2016-06-24" @default.
- W2129719013 creator A5003831287 @default.
- W2129719013 creator A5026602252 @default.
- W2129719013 creator A5045761776 @default.
- W2129719013 creator A5047187243 @default.
- W2129719013 creator A5060370891 @default.
- W2129719013 creator A5062737940 @default.
- W2129719013 date "2008-06-01" @default.
- W2129719013 modified "2023-09-26" @default.
- W2129719013 title "Acute ST-Segment Elevation Myocardial Infarction" @default.
- W2129719013 cites W101335387 @default.
- W2129719013 cites W109722724 @default.
- W2129719013 cites W1232072723 @default.
- W2129719013 cites W1484129406 @default.
- W2129719013 cites W1485646988 @default.
- W2129719013 cites W1519563600 @default.
- W2129719013 cites W1524952854 @default.
- W2129719013 cites W1533600198 @default.
- W2129719013 cites W1553345686 @default.
- W2129719013 cites W1568597842 @default.
- W2129719013 cites W1570337497 @default.
- W2129719013 cites W1572147214 @default.
- W2129719013 cites W1581637922 @default.
- W2129719013 cites W1596397105 @default.
- W2129719013 cites W160665858 @default.
- W2129719013 cites W161671725 @default.
- W2129719013 cites W1763204026 @default.
- W2129719013 cites W1920261218 @default.
- W2129719013 cites W1922348626 @default.
- W2129719013 cites W1954373103 @default.
- W2129719013 cites W1963950792 @default.
- W2129719013 cites W1964788971 @default.
- W2129719013 cites W1966732595 @default.
- W2129719013 cites W1967208504 @default.
- W2129719013 cites W1968075063 @default.
- W2129719013 cites W1968120780 @default.
- W2129719013 cites W1971010543 @default.
- W2129719013 cites W1972083038 @default.
- W2129719013 cites W1972109636 @default.
- W2129719013 cites W1973760359 @default.
- W2129719013 cites W1973877011 @default.
- W2129719013 cites W1974706029 @default.
- W2129719013 cites W1976972921 @default.
- W2129719013 cites W1977452105 @default.
- W2129719013 cites W1982365463 @default.
- W2129719013 cites W1984328181 @default.
- W2129719013 cites W1984761420 @default.
- W2129719013 cites W1987027612 @default.
- W2129719013 cites W1987304112 @default.
- W2129719013 cites W1988171809 @default.
- W2129719013 cites W1990748540 @default.
- W2129719013 cites W1990850219 @default.
- W2129719013 cites W1990876610 @default.
- W2129719013 cites W1991044694 @default.
- W2129719013 cites W1991265888 @default.
- W2129719013 cites W1991341976 @default.
- W2129719013 cites W1993540519 @default.
- W2129719013 cites W1994313737 @default.
- W2129719013 cites W1994718207 @default.
- W2129719013 cites W1995438247 @default.
- W2129719013 cites W1996571048 @default.
- W2129719013 cites W1998245809 @default.
- W2129719013 cites W2000728107 @default.
- W2129719013 cites W2001285874 @default.
- W2129719013 cites W2001663023 @default.
- W2129719013 cites W2001688139 @default.
- W2129719013 cites W2002653515 @default.
- W2129719013 cites W2003972391 @default.
- W2129719013 cites W2006862119 @default.
- W2129719013 cites W2008582695 @default.
- W2129719013 cites W200979310 @default.
- W2129719013 cites W2010280774 @default.
- W2129719013 cites W2010836948 @default.
- W2129719013 cites W2011047627 @default.
- W2129719013 cites W2011870461 @default.
- W2129719013 cites W2012652036 @default.
- W2129719013 cites W2013421239 @default.
- W2129719013 cites W2013808156 @default.
- W2129719013 cites W2014390331 @default.
- W2129719013 cites W2015606026 @default.
- W2129719013 cites W2017132043 @default.
- W2129719013 cites W2020958792 @default.
- W2129719013 cites W2021062980 @default.
- W2129719013 cites W2024352468 @default.
- W2129719013 cites W2027974152 @default.
- W2129719013 cites W2028470404 @default.
- W2129719013 cites W2029351753 @default.
- W2129719013 cites W2030530220 @default.
- W2129719013 cites W2032683105 @default.
- W2129719013 cites W2035015235 @default.
- W2129719013 cites W2038391832 @default.
- W2129719013 cites W2039130243 @default.
- W2129719013 cites W2039422502 @default.
- W2129719013 cites W2040092628 @default.
- W2129719013 cites W2042474425 @default.
- W2129719013 cites W2044129810 @default.
- W2129719013 cites W2044191826 @default.